Suggestions to separate taking levothyroxine from medicines/supplements is very frequent on this forum.
And, yet again, backed up by research.
These women will not have decided on their own, "let us take calcium carbonate after levothyroxine". No, of course not. Some medic, somewhere, will have suggested, advised, maybe prescribed the supplement. And (obviously) failed to make sure the patients understand the need to separate such things from levothyroxine.
Mind, that their conclusion has to speak of not "solely measuring serum TSH" indicates something about their expected audience.
Endocrine. 2019 May;64(2):284-292. doi: 10.1007/s12020-018-1798-7. Epub 2018 Oct 27.
L-thyroxine malabsorption due to calcium carbonate impairs blood pressure, total cholesterolemia, and fasting glycemia.
Morini E1, Catalano A1, Lasco A1, Morabito N1, Benvenga S2,3,4.
Author information
1 Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
2 Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. s.benvenga@live.it.
3 Master Program on Childhood, Adolescent and Women's Endocrine Health, University of Messina, Viale Gazzi, 98125, Messina, Italy. s.benvenga@live.it.
4 Interdepartmental Program of Molecular & Clinical Endocrinology, and Women's Endocrine Health, University Hospital Policlinico G. Martino, Messina, Italy. s.benvenga@live.it.
Abstract
PURPOSE:
Calcium carbonate was previously shown to interfere with L-thyroxine absorption. To estimate the magnitude of tablet L-thyroxine malabsorption caused by calcium carbonate, with resulting increase in serum thyrotropin (TSH), we performed a cohort study in a referral care center.
METHODS:
Fifty postmenopausal hypothyroid L-thyroxine-treated women (age 71.7 ± 5.1 years) who added calcium supplementation (600-1000 mg/day) were considered. They were taking L-thyroxine 45-60 min before breakfast (setting 1). After 4.4 ± 2.0 years from initiation of L-thyroxine therapy, they took calcium supplemaentation within 2 h after L-thyroxine taking (setting 2) for 2.3 ± 1.1 years. Hence, we recommended postponing calcium intake 6-8 h after L-thyroxine (setting 3). We evaluated TSH levels, the prevalence of women with elevated TSH (>4.12 mU/L), total cholesterolemia, fasting glycemia, blood pressure, and the prevalence of hypercholesterolemia, hyperglycemia, and hypertension.
RESULTS:
TSH levels were 3.33 ± 1.93 mU/L versus 1.93 ± 0.51 or 2.16 ± 0.54 comparing setting 2 with setting 1 or 3 (P<0.001, both). In setting 2, 18% women had elevated TSH versus none in setting 1 or 3 (P<0.01). Total cholesterolemia, fasting glycemia, systolic, and diastolic blood pressure were also significantly higher in setting 2 compared to settings 1 and 3. For every 1.0 mU/L increase within the TSH range of 0.85-6.9 mU/L, total cholesterolemia, glycemia, systolic, and diastolic blood pressure increased by 12.1, 3.12 mg/dL, 2.31, and 2.0 mmHg, respectively.
CONCLUSIONS:
Monitoring of hypothyroid patients who ingest medications that decrease L-thyroxine absorption should not be restricted to solely measuring serum TSH.
KEYWORDS:
Blood pressure; Calcium carbonate; Fasting blood glucose; Hypothyroidism; L-thyroxine malabsorption; Serum cholesterol
PMID: 30368654
DOI: 10.1007/s12020-018-1798-7